Leon Ronen, MD
Family Medicine · Scott Depot, WVNPI 1922063577
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,961 of the $8,211 with a category attached, or 84.8%. It is spread thinly across 42 manufacturers, the largest accounting for just 18.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,094, 6.3 times the $490 reported in 2019. Among family medicine clinicians in WV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 366 payments — averaging $22.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Sobi, Inc$1K
- Novo Nordisk$983
- Abbott$539
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$445
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$291
- plus $3K from 36 others
What the payments were for
- Consulting fees$1,25015%
- Food & beverage$6,96185%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G7 GSS (161)$161
- DEXCOM STELO GLUCOSE BIOSENSOR$161
- Otezla$125
- VRAYLAR$125
- CAPLYTA$125
How this compares
$8,211 in reported general payments places this provider in the 90th percentile of 843 family medicine providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 139 | $155,117 |
| JardianceEmpagliflozin | 66 | $99,580 |
| EliquisApixaban | 99 | $87,535 |
| FarxigaDapagliflozin Propanediol | 33 | $44,990 |
| XareltoRivaroxaban | 21 | $32,837 |
| VraylarCariprazine Hcl | 14 | $29,039 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $24,387 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 45 | $24,372 |
| JanuviaSitagliptin Phosphate | 18 | $22,230 |
| EntrestoSacubitril/Valsartan | 12 | $21,217 |
| TrulicityDulaglutide | 19 | $17,990 |
| CreonLipase/Protease/Amylase | 11 | $16,226 |
| MounjaroTirzepatide | 14 | $16,174 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 13 | $10,042 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $9,841 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $983 | $155,117139 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $15 | $106,52381 claims |
| PfizerEliquis | $140 | $87,53599 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $275 | $59,714100 claims |
| AstraZenecaFarxiga, Symbicort | $124 | $47,62545 claims |
| AbbVieVraylar, Creon | $1,502 | $45,26525 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $174 | $34,16433 claims |
| Johnson & JohnsonXarelto | $15 | $32,83721 claims |
| MerckJanuvia | $62 | $22,23018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 843 family medicine providers in West Virginia.
Other family medicine in Scott Depot
- Julie DetempleSouth Charleston$129K
- John CornellHuntington$68K
- Isha WoofterClarksburg$27K
- Dominick WoofterClarksburg$27K
- Ryan RunyonPrinceton$21K
- David HessBridgeport$20K
- Cherry LobatonMartinsburg$19K
- Melissa GamponiaCharleston$18K
- Stephen MascioFollansbee$17K
- Kenneth AdkinsSouth Charleston$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.